Objective: The purpose of this study was to explore the population pharmacokinetic features of moxifloxacin in infected patients.
Method: A total of 37 Chinese adult infected patients were treated with intravenous moxifloxacin (400 mg/day). In total, 67 plasma samples of moxifloxacin were collected immediately after intravenous dripping and before administration on the 3rd, 4th or 5th day. A nonlinear mixed effect model was used to model the population pharmacokinetic (PK) behavior of moxifloxacin. The final population pharmacokinetic models were validated using the bootstrap method. Some covariates, including demographic characteristics and hematological and biological indicators, were analyzed.
Results: A structural model was developed based on a one-compartment model with intravenous infusion and first-order elimination. The typical population values of moxifloxacin for the pharmacokinetic parameters of apparent clearance (CL) and apparent distribution volume (V) were 12.9 L/h and 115 L, respectively. The inter-individual variabilities of CL and V were 36% and 28%, respectively. The covariates of WT influenced the CL and V values determined by the final model.
Conclusion: The present study developed population pharmacokinetic models for moxifloxacin in infected Chinese patients. The results detailed here could provide a reference for individualized moxifloxacin therapy in the clinical setting.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jiac.2014.06.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Population pharmacokinetic modeling and exposure-response analysis of Anrikefon: insights and implications in clinical analgesia.
Expert Rev Clin Pharmacol
January 2025
Department of Medical Cosmetology, Hunan Provincial Hospital of Maternal and Child Health Care.
Background: Anrikefon (HSK21542), a potent and selective peripheral kappa opioid receptor (KOR) agonist developed by Haisco, effectively blocks pain and itch signals.
Aim: To develop a population pharmacokinetic (PK) model for anrikefon and conduct exposure-response (E-R) analysis for safety and efficacy in postoperative pain patients.
Method: The Population PK analysis uses NONMEM software with data from six trials.
Safety, efficacy, and immunogenicity of a novel IgG degrading enzyme (KJ103): results from two randomised, blinded, phase 1 clinical trials.
Gene Ther
January 2025
Shanghai Bao Pharmaceuticals Co., Ltd., No. 28 Luoxin Road, Baoshan, Shanghai, China.
The approved intravenous adeno-associated virus (AAV) therapies are limited by the widespread prevalence of pre-existing anti-AAV antibodies in the general population, which are known to restrict patients' ability to receive gene therapy and limit transfection efficacy in vivo. To address this challenge, we have developed a novel recombinant human immunoglobulin G degrading enzyme KJ103, characterized by low immunogenicity and clinical value for the elimination of anti-AAV antibodies in gene transfer. Herein, we conducted two randomized, blinded, placebo-controlled, single ascending dose Phase I studies in China and New Zealand, to evaluate the pharmacokinetics, pharmacodynamics, safety and immunogenicity of KJ103 in healthy volunteers.
View Article and Find Full Text PDFCola beverage reduces risk of lead poisoning from accidental ingestion of contaminated soil particles in rat and swine models.
Nat Commun
January 2025
School of Environmental Science and Engineering, Shanghai Jiao Tong University, Shanghai, China.
Accidental ingestion of lead (Pb)-contaminated soils represents a major route of Pb exposure for both adults and children, and the development of accessible and cost-effective solutions to reduce Pb poisoning is urgently required. Here, we present an effective and straightforward technique, involving the consumption of cola beverages, for the purpose of lowering blood Pb levels following the ingestion of contaminated soils in animal models. This method facilitated the direct passage of Pb in contaminated soil through the digestive system, enhancing its elimination without absorption into systemic circulation.
View Article and Find Full Text PDFPopulation pharmacokinetics and exposure-response analysis of durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary tract cancer.
Cancer Chemother Pharmacol
January 2025
Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Waltham, MA, USA.
Purpose: Durvalumab in combination with gemcitabine/cisplatin has shown a favorable benefit-risk profile in the TOPAZ-1 study for advanced biliary tract cancers (BTC). This analysis evaluated the population pharmacokinetics (PopPK) of durvalumab, and exposure-response for efficacy and safety (ERES) of TOPAZ-1.
Methods: The PopPK model for durvalumab was updated using data from 5 previously analysed studies and TOPAZ-1.
Individualization of piperacillin dosage based on therapeutic drug monitoring with or without model-informed precision dosing: a scenario analysis.
J Antimicrob Chemother
January 2025
Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Rue du Bugnon 17, 1011, Lausanne, Switzerland.
Background: Model-informed precision dosing (MIPD) combines population pharmacokinetic knowledge with therapeutic drug monitoring (TDM) to optimize dosage adjustment. It could improve target concentration attainment over empirical TDM, still widely practised for broad-spectrum antibiotics.
Objectives: To evaluate the respective performance of TDM and MIPD in achieving target piperacillin exposure.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!